Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.36
CPHI's Cash to Debt is ranked lower than
80% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. CPHI: 0.36 )
Ranked among companies with meaningful Cash to Debt only.
CPHI' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.87 Max: No Debt
Current: 0.36
Equity to Asset 0.73
CPHI's Equity to Asset is ranked higher than
66% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. CPHI: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
CPHI' s Equity to Asset Range Over the Past 10 Years
Min: -10  Med: 0.83 Max: 0.97
Current: 0.73
-10
0.97
F-Score: 6
Z-Score: 0.80
M-Score: -4.72
WACC vs ROIC
9.86%
-7.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -39.41
CPHI's Operating margin (%) is ranked lower than
86% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.87 vs. CPHI: -39.41 )
Ranked among companies with meaningful Operating margin (%) only.
CPHI' s Operating margin (%) Range Over the Past 10 Years
Min: -175.11  Med: 30.15 Max: 39.48
Current: -39.41
-175.11
39.48
Net-margin (%) -45.30
CPHI's Net-margin (%) is ranked lower than
86% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. CPHI: -45.30 )
Ranked among companies with meaningful Net-margin (%) only.
CPHI' s Net-margin (%) Range Over the Past 10 Years
Min: -178.69  Med: 26.44 Max: 39.31
Current: -45.3
-178.69
39.31
ROE (%) -9.68
CPHI's ROE (%) is ranked lower than
77% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.03 vs. CPHI: -9.68 )
Ranked among companies with meaningful ROE (%) only.
CPHI' s ROE (%) Range Over the Past 10 Years
Min: -35.05  Med: 18.78 Max: 82.39
Current: -9.68
-35.05
82.39
ROA (%) -7.17
CPHI's ROA (%) is ranked lower than
77% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. CPHI: -7.17 )
Ranked among companies with meaningful ROA (%) only.
CPHI' s ROA (%) Range Over the Past 10 Years
Min: -28.38  Med: 16.75 Max: 60.23
Current: -7.17
-28.38
60.23
ROC (Joel Greenblatt) (%) -13.39
CPHI's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.38 vs. CPHI: -13.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPHI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46.65  Med: 28.61 Max: 65.47
Current: -13.39
-46.65
65.47
Revenue Growth (3Y)(%) -28.00
CPHI's Revenue Growth (3Y)(%) is ranked lower than
92% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. CPHI: -28.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPHI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -5 Max: 179.1
Current: -28
0
179.1
» CPHI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CPHI Guru Trades in Q3 2015

Jim Simons 108,800 sh (-11.18%)
» More
Q4 2015

CPHI Guru Trades in Q4 2015

Jim Simons 102,300 sh (-5.97%)
» More
Q1 2016

CPHI Guru Trades in Q1 2016

Jim Simons 94,100 sh (-8.02%)
» More
Q2 2016

CPHI Guru Trades in Q2 2016

Jim Simons 95,300 sh (+1.28%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:ECTE, NAS:BSPM, OTCPK:INBP, OTCPK:CHEXF, OTCPK:ENZB, OTCPK:BIVI, OTCPK:INNV, NAS:IMNP, NAS:ALQA, OTCPK:SUWN, NAS:PRPH, OTCPK:FAMDF, AMEX:AXN, NAS:TNXP, NAS:ALIM, AMEX:NNVC, OTCPK:BIOYF, NAS:ASMB, NAS:OASM, NAS:NBRV » details
Traded in other countries:XQJ.Germany,
China Pharma Holding Inc develops, manufactures and markets pharmaceutical products for human use in connection with a high-incidence and high-morality diseases and medical conditions in the People's Republic of China.

China Pharma Holding, Inc., a Delaware corporation was incorporated on January 28, 1999 under the name 'Softstone, Inc.' On March 16, 2006; it changed its corporate name to China Pharma Holdings, Inc. The company develops, manufactures and markets pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions in the People's Republic of China (the 'PRC'). All of its operations are conducted in the PRC, where its manufacturing facilities are located. It manufactures pharmaceutical products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions and granules. All of its pharmaceutical products are sold on a prescription basis and have been approved for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (the 'SFDA') based upon demonstrated safety and efficacy. At December 31, 2012, it manufactured 20 pharmaceutical products for a variety of diseases and medical indications. It markets and sells its products through 16 sales offices covering all major cities and provinces in the PRC. Its product portfolio includes both branded and generic drugs that it either developed or was developed by it in joint research efforts with its academic institutional partners or, to a lesser extent, acquired from third parties. It develops new products in-house as well as through relationships with several research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. The Company sells its prescription drugs to hospitals and clinics through its distribution system which is comprised of 1,220 independent regional distributors. In November 2008, it purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product candidate from a third party laboratory. In connection with that acquisition, it obtained the title of the patent. This patent expires in 2025. At December 31, 2012, it owned 17 registered trademarks, including marks for nine of the 20 pharmaceutical products it manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and Shenkaineng, as well as marks for its AFGF logo, its HPS logo, its two HELPSON logos and four other logos.

Ratios

vs
industry
vs
history
P/B 0.16
CPHI's P/B is ranked higher than
99% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.04 vs. CPHI: 0.16 )
Ranked among companies with meaningful P/B only.
CPHI' s P/B Range Over the Past 10 Years
Min: 0.06  Med: 0.76 Max: 7.96
Current: 0.16
0.06
7.96
P/S 0.67
CPHI's P/S is ranked higher than
88% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. CPHI: 0.67 )
Ranked among companies with meaningful P/S only.
CPHI' s P/S Range Over the Past 10 Years
Min: 0.16  Med: 1.09 Max: 12.68
Current: 0.67
0.16
12.68
PFCF 4.72
CPHI's PFCF is ranked higher than
94% of the 192 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.70 vs. CPHI: 4.72 )
Ranked among companies with meaningful PFCF only.
CPHI' s PFCF Range Over the Past 10 Years
Min: 2.04  Med: 6.11 Max: 350
Current: 4.72
2.04
350
POCF 2.45
CPHI's POCF is ranked higher than
96% of the 248 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.32 vs. CPHI: 2.45 )
Ranked among companies with meaningful POCF only.
CPHI' s POCF Range Over the Past 10 Years
Min: 1.21  Med: 5.46 Max: 44.73
Current: 2.45
1.21
44.73
Shiller P/E 2.30
CPHI's Shiller P/E is ranked higher than
98% of the 154 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.01 vs. CPHI: 2.30 )
Ranked among companies with meaningful Shiller P/E only.
CPHI' s Shiller P/E Range Over the Past 10 Years
Min: 1  Med: 1.5 Max: 2.73
Current: 2.3
1
2.73
Current Ratio 1.69
CPHI's Current Ratio is ranked lower than
68% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. CPHI: 1.69 )
Ranked among companies with meaningful Current Ratio only.
CPHI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 6.47 Max: 23.65
Current: 1.69
0.01
23.65
Quick Ratio 1.06
CPHI's Quick Ratio is ranked lower than
73% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. CPHI: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
CPHI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 4.64 Max: 17.34
Current: 1.06
0.01
17.34
Days Inventory 271.19
CPHI's Days Inventory is ranked lower than
91% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. CPHI: 271.19 )
Ranked among companies with meaningful Days Inventory only.
CPHI' s Days Inventory Range Over the Past 10 Years
Min: 138.59  Med: 218.75 Max: 375
Current: 271.19
138.59
375
Days Sales Outstanding 98.18
CPHI's Days Sales Outstanding is ranked lower than
66% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.29 vs. CPHI: 98.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.18  Med: 280.49 Max: 502.3
Current: 98.18
98.18
502.3
Days Payable 71.32
CPHI's Days Payable is ranked higher than
54% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.16 vs. CPHI: 71.32 )
Ranked among companies with meaningful Days Payable only.
CPHI' s Days Payable Range Over the Past 10 Years
Min: 6.15  Med: 23.72 Max: 71.32
Current: 71.32
6.15
71.32

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.16
CPHI's Price/Tangible Book is ranked higher than
99% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.78 vs. CPHI: 0.16 )
Ranked among companies with meaningful Price/Tangible Book only.
CPHI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.06  Med: 0.87 Max: 6.1
Current: 0.16
0.06
6.1
Price/Projected FCF 0.26
CPHI's Price/Projected FCF is ranked higher than
98% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. CPHI: 0.26 )
Ranked among companies with meaningful Price/Projected FCF only.
CPHI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.08  Med: 0.37 Max: 4.01
Current: 0.26
0.08
4.01
Price/Median PS Value 0.63
CPHI's Price/Median PS Value is ranked higher than
87% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. CPHI: 0.63 )
Ranked among companies with meaningful Price/Median PS Value only.
CPHI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.52 Max: 55
Current: 0.63
0.15
55
Earnings Yield (Greenblatt) (%) -28.20
CPHI's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. CPHI: -28.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPHI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -28.2  Med: 20.5 Max: 139.1
Current: -28.2
-28.2
139.1
Forward Rate of Return (Yacktman) (%) -33.47
CPHI's Forward Rate of Return (Yacktman) (%) is ranked lower than
96% of the 331 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.18 vs. CPHI: -33.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CPHI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -37.2  Med: -1.8 Max: 41.5
Current: -33.47
-37.2
41.5

More Statistics

Revenue (TTM) (Mil) $16.16
EPS (TTM) $ -0.17
Beta1.94
Short Percentage of Float0.05%
52-Week Range $0.12 - 0.35
Shares Outstanding (Mil)43.58
» More Articles for CPHI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CHINA PHARMA HOLDINGS, INC. Financials Aug 19 2016
China Pharma Holdings, Inc. Reports Second Quarter Financial Results Aug 12 2016
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
CPHI to Hold Second Quarter 2016 Earnings Conference Call on Friday August 12, 2016 at 8:30 a.m. ET Aug 01 2016
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
China Pharma Holdings, Inc. Reports First Quarter Financial Results May 17 2016
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 16 2016
CPHI to Hold First Quarter 2016 Earnings Conference Call on Tuesday May 17, 2016 at 8:30 a.m. ET May 05 2016
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 05 2016
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: 2015 By the Numbers Apr 05 2016
China Pharma Holdings, Inc. Reports Full Year 2015 Financial Results Mar 31 2016
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-K, Annual Report Mar 30 2016
CPHI to Hold Fiscal Year 2015 Earnings Conference Call On Thursday March 31, 2016 at 8:30 a.m. ET Mar 18 2016
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q/A, Quarterly Report Dec 28 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-K/A, Annual Report Dec 28 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or... Dec 11 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 10 2015
China Pharma Holdings, Inc. Reports Third Quarter 2015 Financial Results Nov 17 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Nov 16 2015
CPHI to Hold Third Quarter 2015 Earnings Conference Call On Tuesday November 17, 2015 at 8:30 a.m.... Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)